10:31 AM EDT, 05/28/2024 (MT Newswires) -- Vera Therapeutics ( VERA ) said Tuesday the US Food and Drug Administration granted breakthrough therapy designation to atacicept to treat immunoglobulin A nephropathy, also known as Berger's disease, an autoimmune kidney disease.

The FDA reviewed data from a phase 2b trial that showed the stabilization of estimated glomerular filtration rate over 72 weeks of treatment, the company said.

"The stability of eGFR with atacicept represents a substantial potential improvement over currently available therapies," the company said.

Vera shares rose 1.3% in recent trading.

Price: 37.60, Change: +0.49, Percent Change: +1.33